NCT05665088View on ClinicalTrials.gov

Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)

PHASE3TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

December 14, 2022

Primary Completion Date

September 11, 2023

Study Completion Date

September 11, 2023

Conditions
AgitationDementia
Interventions
DRUG

BXCL501

Sublingual Film

DRUG

Matching Placebo

Sublingual Placebo Film

Trial Locations (7)

32117

BioXcel Clinical Research Site, Daytona Beach

32162

BioXcel Clinical Research Site, The Villages

32751

BioXcel Clinical Research Site, Maitland

70072

BioXcel Clinical Research Site, Marrero

90720

BioXcel Clinical Research Site, Los Alamitos

01103

BioXcel Clinical Research Site, Springfield

08755

BioXcel Clinical Research Site, Toms River

Sponsors
All Listed Sponsors
collaborator

Cognitive Research Corporation

INDUSTRY

lead

BioXcel Therapeutics Inc

INDUSTRY